Document Detail


8-Methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis.
MedLine Citation:
PMID:  17100735     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Targeted ultraviolet (UV) phototherapy is a recent addition to the therapeutic armamentarium for the treatment of localized psoriasis. Topical psoralens enhance the therapeutic effects of UV-based treatment for various dermatoses, but have never been used in conjunction with targeted UVB. PURPOSE: To compare the efficacy of targeted narrowband UVB phototherapy (NB-UVB) alone with that of the combination of 0.1% 8-methoxypsoralen cream and targeted NB-UVB phototherapy (8-MOP/NB-UVB) for the treatment of plaque-type psoriasis. METHODS: Two areas within the same lesion of stable psoriasis were randomized to receive either targeted NB-UVB alone or 8-MOP/NB-UVB. Fluences of UVB delivered were held constant at four minimal erythema doses. The treatments were continued until lesions cleared or 12 treatments. Follow-ups were done until lesional scores returned to 50% of the baseline values. RESULTS: Ten patients completed this study. Four lesions were cleared by 8-MOP/NB-UVB while three were cleared by NB-UVB alone. The improvement in disease activity as reflected by psoriasis severity index score during treatment was statistically significantly better in the combination group (P=0.005). Mean remission time of lesions which were cleared by 8-MOP/NB-UVB was 8 weeks while that for lesions that were cleared by NB-UVB alone was 4.67 weeks. CONCLUSION: We concluded that addition of 0.1% 8-MOP cream to targeted narrowband UVB significantly enhances the therapeutic effects of the light treatment without increasing the incidence of adverse effects.
Authors:
Noppadol Amornpinyokeit; Pravit Asawanonda
Related Documents :
12061975 - Onchocerciasis: the clinical and epidemiological burden of skin disease in africa.
12121555 - Rejuvenating facial massage--a bane or boon?
10632395 - Possibility of wound dressing using poly(l-leucine)/poly(ethylene glycol)/poly(l-leucin...
8165735 - Leishmaniasis of the nose caused by different species of leishmania in the sudan. disti...
12566955 - Projection of creutzfeldt-jakob disease frequency based on cadaveric dura transplantati...
19094825 - Travelers as a sentinel population: use of sentinel networks to inform pretravel and po...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Photodermatology, photoimmunology & photomedicine     Volume:  22     ISSN:  0905-4383     ISO Abbreviation:  Photodermatol Photoimmunol Photomed     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-11-14     Completed Date:  2007-02-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9013641     Medline TA:  Photodermatol Photoimmunol Photomed     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  285-9     Citation Subset:  IM    
Affiliation:
Division of Dermatology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Adolescent
Adult
Combined Modality Therapy
Dermatologic Agents / administration & dosage,  therapeutic use*
Female
Humans
Male
Methoxsalen / administration & dosage,  therapeutic use*
Middle Aged
Psoriasis / drug therapy*,  pathology,  radiotherapy*
Severity of Illness Index
Treatment Outcome
Ultraviolet Rays*
Chemical
Reg. No./Substance:
0/Dermatologic Agents; 298-81-7/Methoxsalen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cloning and identification of EDD gene from ultraviolet-irradiated HaCaT cells.
Next Document:  Failure of physiologic doses of pure UVA or UVB to induce lesions in photosensitive cutaneous lupus ...